Postdoctoral position available immediately to investigate the molecular and cellular basis of neurodegeneration, with an emphasis on Alzheimer's and Parkinson's disease. The position is joint between the laboratory of Professors Mel Feany at Harvard Medical School and Ernest Fraenkel at MIT. These labs collaborate on a multidisciplinary approach integrating systems biology approaches, biochemistry, cell biology, genetics (Drosophila and vertebrate disease models, human) and analysis of human postmortem tissue. The successful applicant will have strong experimental training in a related area and a willingness to work closely with computational scientists.
No prior computational experience is expected.
Position includes substantial commitment to mentoring and professional development.
The Feany Lab at Harvard Medical School has created fruit fly models of human neurological diseases, including Alzheimer's disease, Parkinson's disease, and a number of less common disorders. We have used these models to study the pathogenesis of the human disorders, with an emphasis on unbiased forward genetic screens. Candidate pathways and mechanisms discovered through large scale screening in flies are then validated in a variety of mammalian systems, including rodent models, patient derived neurons and glia, and patient samples.
The Fraenkel Lab at the Massachusetts Institute of Technology develops computational and experimental approaches to search for new therapeutic strategies for diseases. New experimental methods make it possible to measure cellular changes across the genome and proteome. These technologies include genome-wide measurements of transcription, of protein-DNA interactions, of genetic interactions, of protein modifications and metabolites. Each data source provides a very narrow view of the cellular changes. However, by computationally integrating these data we can reconstruct signaling pathways and identify previously unrecognized regulatory mechanisms tha...t contribute to the etiology of disease and may provide new approaches for treatment. We are applying these methods to a wide range of neurodegenerative diseases.